161Tb-labeled radiopharmaceuticals targeting mucin receptors for treatment of pancreatic cancer KU Leuven
Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadliest cancers worldwide with a five-year survival rate of less than 10%. To improve patient prognosis, there is an urgent need for the development of more effective therapeutic strategies. Targeted radionuclide therapy (TRNT) is an established, evidence-based treatment modality where a radioactive ligand (i.e. radiopharmaceutical) is injected intravenously allowing targeted ...